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A B S T R A C T
The ATP-binding cassette, sub-family A, member 1 gene (ABCA1) is a relevant positional and functional can-
didate gene for Alzheimer’s disease (AD). A case-control association study of genetic variations covering the
ABCA1 locus was performed in relation to AD risk in a Hungarian sample. Five single nucleotide polymorphisms
(rs2422493: C-477T, rs2740483: G-17C, rs2230805: G474A/L158L, rs2230806: G656A/R219 K and rs2066718:
G2311A/V771 M) were genotyped in 431 AD patients and 302 cognitively healthy, elderly controls. In single
marker analysis, signiﬁcant associations were found in the case of rs2230805 and rs2230806 polymorphisms: the
minor A allele containing genotypes for both polymorphisms were more frequent in the control compared to the
AD group. Haplotype analysis revealed that rs2230805, rs2230806 and rs2066718 polymorphisms created a
linkage disequilibrium (LD) block with a strong LD between rs2230805 and rs2230806 polymorphisms. In the
haplotype risk association tests, A-A-G haplotype of the rs2230805-rs2230806-rs2066718 polymorphisms was
found to be nominally signiﬁcantly more frequent in the control group. After correcting p values for multiple
testing, only the eﬀects of the rs2230805 and rs2230806 polymorphisms remained signiﬁcant in the recessive
model suggesting a modest protective eﬀect of their minor alleles in AD, which should be interpreted with
considerable caution, until further studies elucidate their role in AD pathology.
1. Introduction
The non-familial late-onset (> 65 years of age at-onset) form of
Alzheimer’s disease (AD) is most likely caused by a complex interaction
of genetic and environmental factors. The most predictive genetic risk
factor for late-onset AD is the ε4 variant of the apolipoprotein E (APOE;
MIM#107741) gene. The APOE ε2/ε3/ε4 isoforms (deﬁned by
rs429358 and rs7412 polymorphisms) inﬂuence the lipid compounds of
the cell membrane and thereby the cleavage of the amyloid-β protein
precursor (AβPP) creates aggregation prone amyloid-ß (Aß) peptides
[25]. The common genetic variants that have been associated with late-
onset AD other than APOE ε4 allele have small eﬀect sizes and still a
great portion of the predicted heritability for AD remains unrevealed
[14].
The ATP-binding cassette, sub-family A, member 1 gene (ABCA1;
MIM# 600046) is a positional and functional candidate gene for AD.
The ABCA1 gene is located near to an AD linkage peak on chromosome
9 at position q22 [2,18,19]. The encoded product of the ABCA1 gene is
a membrane-associated transporter that functions as an eﬄux pump for
cholesterol and phospholipids from cell membranes to lipid-free apo-
lipoprotein A-I (apoA-I) and apoE in the cellular lipid removal pathway
[13,28].
Controlling apoE lipidation, ABCA1 likely has a role in the patho-
genesis of AD, which is supported by a number of studies reporting
signiﬁcant impact of ABCA1 on Aβ deposition and clearance in AD
model mice [11]. AβPP transgenic mice lacking the ABCA1 gene have
increased Aβ deposition and cognitive decline with diminished levels of
soluble apoE, while transgenic mice overexpressing ABCA1 in the brain
have fewer Aβ plaques [11].
In humans, genetic studies further support the involvement of
ABCA1 in AD. The strongest indication for investigating the relation-
ship between lipid metabolism and neurodegeneration came from the
association of APOE gene variants and the risk for late-onset AD.
Genetic variations of the ABCA1 gene have been studied extensively in
relation to cholesterol metabolism and neurodegeneration after two
important discoveries. Mutations in the ABCA1 gene were reported as
the primary cause of Tangier disease characterized by extremely low
levels of high density lipoprotein [3,4,24]. Non-synonymous common
genetic variation in the ABCA1 gene was found to be associated with
altered lipoprotein levels and a modiﬁed risk for coronary artery dis-
ease [6].
Several case-control association studies attempted to reveal the
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relationship between ABCA1 common polymorphisms and AD sus-
ceptibility; however, despite the biological plausibility of this locus as a
modulator of AD risk, contradictory results were reported (positive
ﬁndings: [10,20,22,26,27,31–33] negative results: [5,12,15] meta-ana-
lyses: [9,30]). In a recent study all ABCA1 coding regions were se-
quenced and found to have a signiﬁcantly higher proportion of rare
non-synonymous variants in the control compared the AD group sug-
gesting a protective eﬀect [16].
The present association study was designed to give further data on
ﬁve potentially relevant single nucleotide polymorphisms (SNPs) in a
well-deﬁned Hungarian sample. SNPs selected for this study consisted
of two promoter polymorphisms (rs2422493: C-477T and rs2740483:
G-17C), and three gene variants – synonymous (rs2230805: G474A/
L158L) and non-synonymous (rs2230806: G656A/R219 K and
rs2066718: G2311A/V771 M) – in the coding region. Applying single-
marker and haplotype analyses, we aimed to evaluate the possible as-
sociation of the above mentioned ABCA1 genetic variations with the
susceptibility to late-onset AD either alone or in epistasis with APOE ε2/
ε3/ε4 polymorphism.
2. Subjects and methods
Our case-control study population consisted of 431 patients with
late-onset AD (74.6 ± 6.8 years of age (mean ± SD), men 34.5%) and
302 cognitively healthy, elderly control individuals (74.1 ± 7.2 years
of age (mean ± SD), men 35.5%) of Hungarian Caucasian descent.
Demographic characteristics of the investigated groups are presented in
Table 1. The AD patients were recruited from the Memory Clinic of the
Department of Psychiatry, University of Szeged, Hungary. All diagnoses
of late-onset AD were set according to the National Institute of Neu-
rological and Communicative Disorders and Stroke/Alzheimer’s Disease
and Related Disorders Association (NINCDS/ADRDA) criteria [17]. No
patient had a family history raising suspicion of familial AD and the
minimum age at onset was 65 years.
Global cognitive performance was measured by the Mini-Mental
State Examination (MMSE). The mean MMSE score in the AD group was
17.5 ± 5.6 (mean ± SD), while in the control group MMSE scores
were higher than 28 points and none of the control individuals had any
veriﬁed symptoms of dementia. The clinical evaluation of all study
participants was set without any prior knowledge of genetic back-
ground. All recruitment and protocols were conducted with written
informed consent and with the approval of the Ethics Committee of the
Hungarian Council on Science and Health (ETT-TUKEB).
Blood was drawn by venous puncture, and genomic DNA was ex-
tracted from whole blood by standard procedures using the Roche High
Pure PCR Template Preparation Kit (Roche Holding AG, Basel,
Switzerland). Genotyping of the investigated polymorphisms was per-
formed by applying commercial TaqMan single-nucleotide poly-
morphism assays (Thermo Fisher Scientiﬁc/Applied Biosystems/,
Waltham, Massachusetts, USA). The polymerase chain reaction ampli-
ﬁcation was conducted in single-plex reactions in 96-well plates with a
total volume of 20 μl using the following ampliﬁcation protocol: 95 °C
for 10 min, and 40 cycles of 92 °C for 15 s, and 60 °C for 1 min.
Fluorescence measurements were performed using the CFX96 Touch
Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules,
CA).
Controls and AD patients were analyzed using t-test for continuous
parameters (MMSE and age), whereas Fisher’s exact and Pearson chi-
square tests were used when categorical parameters (gender, allele and
genotype frequencies) were compared. Binary logistic regression model
was used to test for interaction between the ABCA1 and APOE poly-
morphisms, and to calculate odds ratios (ORs) with 95% conﬁdence
intervals (CIs). To exclude Type I errors, we carried out Bonferroni’s
correction for multiple testing for 5 single-marker genotype compar-
isons in the genotypic model, 2 single-marker genotype comparisons in
the recessive model for rs2230805 and rs2230806, and 5 haplotype
comparisons.
All SNPs were tested for deviation from Hardy-Weinberg equili-
brium (HWE) by Pearson chi-square test. The software Haploview 4.2
was used to conduct linkage disequilibrium (LD) calculations, haplo-
type analyses and to create LD blocks [1]. Power analysis was per-
formed using G*Power 3.0 software [8], and the eﬀect size was de-
termined according to the method published by Cohen [7]. Based on
the calculated eﬀect sizes (w = 0.207 for rs2230805 and w= 0.173 for
rs2230806), our study sample has 99% power at the signiﬁcance level
of 0.05 to detect diﬀerences in rs2230805 and rs2230806 genotype
frequencies between AD and control groups. Given the calculated eﬀect
sizes (w = 0.106 for rs2422493, w = 0.124 for rs2740483,
w = 0.1181 for rs2066718) comparing the diﬀerent genotype fre-
quencies between the two investigated groups, our study population
has a power of 73% for rs2422493, 86% for rs2740483 and 82% for
rs2066718 at the signiﬁcance level of 0.05.
3. Results
A total of 733 samples were analyzed, including 431 AD patients
and 302 elderly, cognitively healthy controls. Comparing the back-
ground parameters, no signiﬁcant diﬀerences were found between AD
cases and controls in mean age or in the distribution of genders, while
MMSE mean scores were shown to diﬀer signiﬁcantly. Genotype fre-
quencies were in agreement with HWE for both AD patients and con-
trols. As shown in Table 1, the APOE ε3/ε4 and ε4/ε4 genotypes were
signiﬁcantly over-represented in the AD group as compared to the
control group (χ2 = 75.995 (5) p < 0.001).
Genotype frequencies of the investigated ABCA1 gene variants are
summarized in Table 2. Genotype distributions of the rs2422493,
rs2740483 and rs2066718 polymorphisms did not diﬀer signiﬁcantly
between the AD and control groups (rs2422493: χ2 = 1.954 (2)
p= 0.376; rs2740483: χ2 = 2.958 (2) p= 0.228; rs2066718:
χ2 = 2.358 (2) p= 0.308). The frequency of the rs2230805 G/G gen-
otype was signiﬁcantly higher in the AD than in the control group
(χ2 = 7.787 (2) p= 0.020, corrected: p= 0.100). Compared to the
controls, the rs2230806 G/G genotype was more frequent in the AD
group (χ2 = 5.245 (2) p= 0.073, corrected: p= 0.365).
As the minor A allele containing genotypes (A+) occurred more
frequently in the control group for both rs2230805 and rs2230806
polymorphisms, a recessive model was also applied, and signiﬁcant
diﬀerences were found when G/G and A+ genotype frequencies were
compared between cases and controls (Fisher’s exact test: rs2230805:
p= 0.011, corrected: p= 0.022; rs2230806: p= 0.024, corrected:
p= 0.048).
The presence of the rs2230805 A allele signiﬁcantly decreased the
risk for AD considering G/G genotype carriers as reference category
(OR = 0.674; 95% CI: 0.501-0.906; p= 0.009). Similarly, the A+
genotype of the rs2230806 polymorphism also showed a signiﬁcantly
Table 1
Demographic characteristics and APOE genotype frequencies of the investigated groups.
AD patients Controls
age (years; mean ± SD) 74.6 ± 6.8 74.1 ± 7.2
sex (male/female (%)) 34.5%/65.5% 35.5%/64.5%
MMSE (scores; mean ± SD) 17.5 ± 5.6 > 28
APOE genotypes*
ε2/ε2 n (%) 0 (0.0%) 4 (1.3%)
ε2/ε3 n (%) 19 (4.4%) 28 (9.3%)
ε2/ε4 n (%) 10 (2.3%) 6 (2.0%)
ε3/ε3 n (%) 200 (46.4%) 209 (69.2%)
ε3/ε4 n (%) 169 (39.2%) 54 (17.9%)
ε4/ε4 n (%) 33 (7.7%) 1 (0.3%)
AD: Alzheimer’s disease, MMSE: Mini Mental State Examination, APOE genotypes(*):
apolipoprotein E genotypes deﬁned by rs429358 and rs7412 polymorphisms.
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decreased risk for AD when G/G genotype was the reference category
(OR = 0.709; 95% CI: 0.528-0.953; p= 0.023). None of the in-
vestigated polymorphisms showed epistasis with APOE ε4 allele on AD
risk in the logistic regression model (p > 0.05).
As shown in the LD plot for the genotyped ABCA1 polymorphisms in
Fig. 1, strong LD was detected between the rs2422493 and rs2740483
(D’: 0.941; r2: 0.322) and between the rs2230805 and rs2230806
polymorphisms (D’: 0.92; r2: 0.766); whereas moderate LD was found
between the SNPs rs2230806 and rs2066718 (D’: 0.766; r2: 0.058). Two
haplotype blocks were observed: rs2422493-rs2740483 (block 1) and
rs2230805-rs2230806- rs2066718 (block 2). The most common
haplotypes were T-G in block 1, and G-G-G and A-A-G in block 2 in both
the AD and control groups.
In the haplotype risk association tests, block 1 showed no associa-
tion with AD risk, but in block 2 a nominally signiﬁcant association was
found, as presented in Table 3. The G-G-G haplotype of the block 2
polymorphisms was more frequent, but not signiﬁcantly, in the AD than
in the control group (χ2 = 0.154 (1) p= 0.116; corrected p= 0.580),
while the A-A-G haplotype had a signiﬁcantly higher occurrence in the
control group (χ2 = 0.0307 (1) p= 0.016, corrected: p= 0.080).
4. Discussion
We investigated the association between genetic variations in the
ABCA1 gene and AD susceptibility applying single-marker and haplo-
type analyses of ﬁve markers in the promoter and in the coding regions.
Single marker case-control analysis revealed signiﬁcant associations for
rs2230805 and rs2230806 polymorphisms in the recessive model,
which remained signiﬁcant after correcting p values with Bonferroni’s
correction for multiple testing.
The minor A allele containing genotypes of the rs2230805 poly-
morphism were over-represented in controls compared to AD cases,
therefore the presence of the A allele lessened the susceptibility to AD
considering G/G genotype carriers as reference. Similarly, the presence
of the rs2230806 minor A allele occurred more frequently in the control
sample and associated with decreased AD risk when G/G genotype was
the reference category. The genotype distributions of the rs2422493,
rs2740483 and rs2066718 polymorphisms were similar in the AD and
control groups without a statistically signiﬁcant diﬀerence. No inter-
actions were observed between APOE and the investigated ABCA1
polymorphisms on diagnosis of AD.
Pairwise LD estimation revealed two haplotype blocks: rs2422493-
rs2740483 (block 1) and rs2230805-rs2230806-rs2066718 (block 2)
with strong (between rs2422493 and rs2740483, and between
rs2230805 and rs2230806 polymorphisms), and moderate LD (between
rs2230806 and rs2066718 polymorphisms) in our sample. In haplotype
analysis a nominally signiﬁcant association was found in the case of
block 2. The A-A-G haplotype frequency was signiﬁcantly higher in the
control compared to the AD group; however, it did not remain sig-
niﬁcant after correcting for multiple testing. These results are in line
with the single-marker ﬁndings that the minor alleles of the strongly
linked rs2230805 and rs2230806 polymorphisms were found to be
over-represented among controls in the single-marker analysis as well.
This is the ﬁrst study investigating the Hungarian population, and
according to the power estimation our medium sample size proved to be
suﬃcient to detect diﬀerences in the genotype frequencies of the in-
vestigated ABCA1 polymorphisms between AD and control samples.
Table 2
Genotype frequencies of the investigated ABCA1 polymorphisms.
Chromosomal localization Polymorphisms AD patients Controls
9:104928714 rs2422493
C/C 124 (28.8%) 75 (24.8%)
C/T 196 (45.5%) 152 (50.4%)
T/T 111 (25.7%) 75 (24.8%)
9:104928254 rs2740483
G/G 231 (53.6%) 155 (51.3%)
G/C 158(36.7%) 126 (41.7%)
C/C 42 (9.7%) 21 (7.0%)
9:104861748 rs2230805
G/G 245 (56.8%) 142 (47.0%)
G/A 151 (35.0%) 136 (45.0%)
A/A 35 (8.2%) 24 (8.0%)
9:104858586 rs2230806
G/G 231(53.6%) 136 (45.0%)
G/A 163 (37.8%) 134 (44.4%)
A/A 37 (8.6%) 32 (10.6%)
9:104826974 rs2066718
G/G 394 (91.4%) 281 (93.0%)
G/A 37 (8.6%) 20 (6.6%)
A/A n.d. 1 (0.4%)
AD: Alzheimer’s disease, ABCA1: ATP-binding cassette transporter subfamily A member
1, n.d.: not detected
Fig. 1. Linkage disequilibrium characteristics of the investigated ABCA1 polymorphisms:
schematic representation of D’ coeﬃcients by pairs of SNPs. Haplotype blocks are
rs2422493-rs2740483 (block 1) and rs2230805-rs2230806-rs2066718 (block 2).
Table 3
Haplotype frequencies of the investigated ABCA1 rs2422493-rs2740483 (block 1) and
rs2230805-rs2230806-rs2066718 (block 2) polymorphisms.
Haplotypesa AD patients Controls Chi-square P value
Block1
T-G 47.8% 49.6% 0.543 0.461
C-C 27.4% 27.5% 0.006 0.937
C-G 24.8% 22.9% 0.563 0.453
Block 2
G-G-G 69.8% 65.8% 2.464 0.117
A-A-G 20.9% 26.2% 5.77 0.016
G-A-G 3.8% 3.4% 0.000 0.983
A-A-A 3.6% 3.3% 0.116 0.733
A-G-G 1.9% 1.3% 1.672 0.196
AD: Alzheimer’s disease, ABCA1: ATP-binding cassette transporter subfamily A member
1.
a Haplotypes of the ABCA1 rs2422493-rs2740483 (block 1) and rs2230805-rs2230806-
rs2066718 (block 2) polymorphisms. Chi-squares and p values for comparisons of the
haplotype frequencies were determined by using the software Haploview 4.2 p.
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The ABCA1 genotype distributions observed in our control sample are
comparable to earlier reports on other control populations of Caucasian
origin [12,23,31,32].
Regarding the two investigated promoter SNPs (rs2422493 and
rs2740483), two previous reports did not detect signiﬁcant association
with susceptibility to AD [22,27], while another study showed an as-
sociation of the rs2422493 T/T genotype with the disease [31]. Sig-
niﬁcant interaction eﬀects on AD risk were also detected for rs2422493
with polymorphisms in genes involved in cholesterol synthesis and
transport [21,23].
Our two positive ﬁndings include the strongly linked markers
rs2230805 and rs2230806. The synonymous coding variant rs2230805
(G474A/L158L) is located in the last exon of the only putative alter-
native splice-form of ABCA1 comprised 5 exons with as yet unknown
function [20]. It is not clear if rs2230805 polymorphism diﬀerentially
aﬀects the binding of common splicing factors. Similarly to our results,
a signiﬁcant association was found between the common allele and the
risk for AD in a large comprehensive Swedish study [20]. The putative
risk variant also had a modest, but signiﬁcant eﬀect on cerebrospinal
ﬂuid (CSF) levels of Aβ42 with the same tendency as APOE ε4 allele,
which is also associated with both increased risk and reduced CSF Aβ42
levels [20].
The most extensively studied rs2230806 non-synonymous poly-
morphism is a nucleotide variation in exon 7 (G656A) which results in
an amino acid change at position 219 (R219K). Inconsistent results
were reported for this SNP; the conclusions ranged from no association
to the minor allele increasing the risk [22,26,27] or decreasing the risk
[20,29,33] for the development of AD. Our ﬁndings strengthen the
results reporting a protective eﬀect on AD risk for the minor allele.
Similar to our ﬁndings, no eﬀect on AD susceptibility of the
rs2066718 non-synonymous polymorphism in exon 16 (G2311A/
V771M) was observed in a previous study [31]. On the other hand,
reports of conﬂicting results can also be found, although both positive
ﬁndings were detected only in a subset of the investigated samples
[10,15].
5. Conclusion
In conclusion, our ﬁndings of a decreased susceptibility to AD for
the minor alleles of the rs2230805 and rs2230806 strongly linked
common polymorphisms suggest a modest protective eﬀect and support
the involvement of ABCA1 gene in AD pathology. The ﬁndings and
conclusions of our study should be interpreted with caution in light of
our medium sample size, limited number of investigated markers and
previous inconsistent results until further replication and functional
assays provide convergent support.
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